Synthesis of Novel Glycolipid Mimetics of Heparan Sulfate and Their Application in Colorectal Cancer Treatment in a Mouse Model

Chem Asian J. 2022 Jun 15;17(12):e202200228. doi: 10.1002/asia.202200228. Epub 2022 Apr 29.

Abstract

Heparan sulfate (HS) is a highly sulfated natural carbohydrate that plays crucial roles in cancer, inflammation, and angiogenesis. Heparanase (HPSE) is the sole HS degrading endoglycosidase that cleaves HS at structure-dependent sites along the polysaccharide chain. Overexpression of HPSE by cancer cells correlates with increased tumor size and enhanced metastasis. Previously we have shown that a tetramer HS mimetic is a potent HPSE inhibitor displaying remarkable anticancer activity in vivo. Building on that work, we report the synthesis and testing of a novel library of single entity trimer glycolipid mimetics that effectively inhibit HPSE at low nanomolar concentrations. A lipophilic arm was introduced to assess whether an improvement of pharmacokinetics and plasma residence time would offset the reduction in charge and multivalency. Preclinical tests in a mouse syngeneic model showed effective tumor growth inhibition by the tetramer but not the trimer glycomimetic.

Keywords: Carbohydrates; Colorectal cancer; Glycolipids; Heparan Sulfate; Heparin; Molecular modelling.

MeSH terms

  • Animals
  • Colorectal Neoplasms* / drug therapy
  • Glycolipids* / pharmacology
  • Heparitin Sulfate / pharmacology
  • Mice
  • Neovascularization, Pathologic

Substances

  • Glycolipids
  • Heparitin Sulfate